P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.

• Tamar Tadmor,
• Guy Melamed,
• Hilel Alapi,
• Sivan Gazit,
• Tal Patalon,
• Lior Rokach

Affiliations

Tamar Tadmor

1 Bnai Zion Medical Center, Hematoology, Haifa, Israel

Guy Melamed

2 Maccabi Healthcare Services, Kahn Sagol Maccabi (KSM) Research & Innovation Center, Tel Aviv, Israel

Hilel Alapi

3 Maccabi Healthcare Services, Kahn Sagol Maccabi (KSM) Research & Innovation Center,, Tel-Aviv, Israel

Sivan Gazit

2 Maccabi Healthcare Services, Kahn Sagol Maccabi (KSM) Research & Innovation Center, Tel Aviv, Israel

Tal Patalon

3 Maccabi Healthcare Services, Kahn Sagol Maccabi (KSM) Research & Innovation Center,, Tel-Aviv, Israel

Lior Rokach

4 Ben-Gurion University of the Negev, Department of Software and Information System Engineering, Beer-Sheva, Israel